New injection could curb heavy drinking in people with obesity
NCT ID NCT06987513
First seen Nov 19, 2025 · Last updated May 01, 2026 · Updated 20 times
Summary
This study tests a weekly injection called pemvidutide to see if it can reduce heavy drinking in adults with alcohol use disorder who are also overweight or have obesity. About 100 participants will receive either the drug or a placebo for 24 weeks. The main goal is to see if the drug lowers the number of heavy drinking days per week.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER (AUD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Altimmune Clinical Study Site
Los Angeles, California, 90038, United States
-
Altimmune Clinical Study Site
Aurora, Colorado, 80045, United States
-
Altimmune Clinical Study Site
New Haven, Connecticut, 06511, United States
-
Altimmune Clinical Study Site
Fort Myers, Florida, 33912, United States
-
Altimmune Clinical Study Site
University Park, Florida, 34201, United States
-
Altimmune Clinical Study Site
North Canton, Ohio, 44720, United States
-
Altimmune Clinical Study Site
Tulsa, Oklahoma, 74136, United States
-
Altimmune Clinical Study Site
Philadelphia, Pennsylvania, 19104, United States
-
Altimmune Clinical Study Site
Providence, Rhode Island, 02923, United States
-
Altimmune Clinical Study Site
Charleston, South Carolina, 29425, United States
-
Altimmune Clinical Study Site
Charlottesville, Virginia, 22903, United States
-
Altimmune Clinical Study Site
Richmond, Virginia, 23298, United States
Conditions
Explore the condition pages connected to this study.